BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 10717254)

  • 1. Natural history of hepatitis C and the impact of anti-viral therapy.
    Boyer N; Marcellin P
    Forum (Genova); 2000; 10(1):4-18. PubMed ID: 10717254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.
    Leone N; Rizzetto M
    Minerva Gastroenterol Dietol; 2005 Mar; 51(1):31-46. PubMed ID: 15756144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ribavirin in the treatment of hepatitis C.
    Abonyi ME; Lakatos PL
    Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of hepatitis C: patients with normal aminotransferase levels.
    Marcellin P; Lévy S; Erlinger S
    Hepatology; 1997 Sep; 26(3 Suppl 1):133S-136S. PubMed ID: 9305678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute hepatitis C: response to treatment with interferon-alpha plus ribavirin].
    Vega Palomares R; Planas Vilà R; Durández Lazaro R; Fábregas Puigtió S
    Gastroenterol Hepatol; 2002 Oct; 25(8):483-6. PubMed ID: 12361528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy of hepatitis C: patients with cirrhosis.
    Schalm SW; Fattovich G; Brouwer JT
    Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
    Masarone M; Persico M
    Expert Rev Anti Infect Ther; 2011 May; 9(5):535-43. PubMed ID: 21609265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up study of sustained biochemical responders with interferon therapy.
    Shindo M; Hamada K; Oda Y; Okuno T
    Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of hepatitis C viral RNA in cirrhotic patients with antiviral therapy.
    Ono SK; da Silva LC; Carrilho FJ; da Fonseca LE; Mendes LC; Madruga CL; Farias Ade Q; Laudanna AA
    Rev Hosp Clin Fac Med Sao Paulo; 1996; 51(5):180-3. PubMed ID: 9216095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and clinical aspects on hepatitis C.
    Higuchi M; Tanaka E; Kiyosawa K
    Jpn J Infect Dis; 2002 Jun; 55(3):69-77. PubMed ID: 12195046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
    Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
    Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.